Aromasin and Radiculopathy - a phase IV clinical study of FDA data

Summary:

Radiculopathy is reported as a side effect among people who take Aromasin (exemestane), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Zometa, and have Neoplasm malignant.

The phase IV clinical study analyzes which people have Radiculopathy when taking Aromasin. It is created by eHealthMe based on reports of 12,620 people who have side effects when taking Aromasin from the FDA, and is updated regularly.

What is Aromasin?

Aromasin has active ingredients of exemestane. It is often used in breast cancer. eHealthMe is studying from 12,863 Aromasin users. Check the latest studies of Aromasin.

What is Radiculopathy?

Radiculopathy (a set of conditions in which one or more nerves is affected and does not work properly) is found to be associated with 739 drugs and 608 conditions by eHealthMe. Check the latest studies of Radiculopathy.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

12,620 people reported to have side effects when taking Aromasin.
Among them, 70 people (0.55%) have Radiculopathy.

Among these 70 people:

How long have people been on Aromasin when they have Radiculopathy? *

What is the gender of people who have Radiculopathy when taking Aromasin? *

female: 95.52 %
male: 4.48 %

What is the age of people who have Radiculopathy when taking Aromasin? *

What are other drugs people take besides Aromasin? *

What are other side effects people have besides Radiculopathy? *

Injury: 64 people, 91.43%
Pain: 64 people, 91.43%
Stress And Anxiety: 63 people, 90.00%
Intervertebral Disc Degeneration (spinal disc degeneration): 56 people, 80.00%
High Blood Pressure: 55 people, 78.57%
Weakness: 53 people, 75.71%
Spinal Column Stenosis (narrowing of spinal column): 53 people, 75.71%
Emotional Distress: 53 people, 75.71%
Swelling: 53 people, 75.71%
Hypophagia (reduced food intake): 52 people, 74.29%

What are the existing conditions these people have? *

Calcium Deficiency (lack of calcium): 34 people, 48.57%
Metastases To Spine (cancer spreads to spine): 34 people, 48.57%
Neoplasm Malignant (cancer tumour): 34 people, 48.57%
Lung Neoplasm (tumour of lung): 33 people, 47.14%
Multiple Myeloma (cancer of the plasma cells): 19 people, 27.14%
Metastases To Bone (cancer spreads to bone): 5 people, 7.14%
Pain: 4 people, 5.71%
High Blood Pressure: 3 people, 4.29%
Anaemia (lack of blood): 3 people, 4.29%
Breast Cancer Female: 2 people, 2.86%

* Approximation only. Some reports may have incomplete information.

Do you take Aromasin and have Radiculopathy?

- Check whether Radiculopathy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Aromasin:

Aromasin (12,863 reports)

Radiculopathy treatments and more:

Radiculopathy (5,655 reports)

Browse all side effects of Aromasin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Radiculopathy:

Radiculopathy (739 drugs)

Browse all the conditions that are associated with Radiculopathy:

Radiculopathy (608 conditions)

Related publications that referenced our studies

Foroughipour M, Farzadfard MT, Aghaee M, Ghabeli-Juibary A, Rezaietalab F, "Methamphetamine Related Radiculopathy: Case Series and Review of Literature", Asia Pacific Journal of Medical Toxicology, 2013 Jun .
Foroughipour M, Farzadfard MT, Aghaee M, Ghabeli-Juibary A, Rezaietalab F, "Methamphetamine Related Radiculopathy: Case Series and Review of Literature", Asia Pacific Journal of Medical Toxicology, 2013 Jun .

How the study uses the data?

The study uses data from the FDA. It is based on exemestane (the active ingredients of Aromasin) and Aromasin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.